Positioning of Molecular Markers in Clinical Routine for the Management of Patients With Adrenal Cancers/Tumors (COMETE-CARE)
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 22, 2023
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The COMETE-CARE trial is studying how to better use specific molecular markers—biological indicators that can help guide treatment—in patients with adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytomas/paragangliomas (MPP). The goal is to make these markers a standard part of care for patients, meaning they could help doctors decide how to treat their patients more effectively after surgery. Researchers want to see how quickly these test results can be provided and how useful they are in managing patients' care.
To be eligible for this trial, participants must be 18 years or older and have an adrenal tumor that is likely cancerous. They should be scheduled for surgery to remove the tumor and must agree to participate by signing a consent form. Throughout the trial, participants will have their biomarkers tested to provide valuable information about their cancer and treatment options. This study is important because it aims to improve the way adrenal cancers are treated and monitored, potentially leading to better outcomes for patients.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Patients 18 years of age and older
- • Patients with an adrenal tumor who will be operated of a potentially malignant adrenocortical carcinoma (ACC) or pheochromocytoma or paraganglioma (MPP) (any stage, any secretion)
- • Patients affiliated with a social security regime
- • Patients who have signed an informed consent
- • Exclusion Criteria
- • Vulnerable populations : minors, pregnant or breastfeeding women, protected adults
- • Patients on AME (state medical aid)
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Anne JOUINOT, Dr
Study Director
APHP
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials